 Motus GI Holdings, Inc., NASDAQ: MOTS Motus GI or the Company, a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced receiving CE Conformité Européene Mark approval for the GEN2 Pure-Vu System. The Company is assessing potential strategic partnership opportunities for the Pure-Vu System with established medical device companies and distributors with commercial operations across the EU. 